Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q

[1]  B. Ebert,et al.  Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome , 2019, Leukemia.

[2]  You-yang Zhao,et al.  β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q). , 2017, Cancer research.

[3]  Anna L. Brown,et al.  DDX41-related myeloid neoplasia. , 2017, Seminars in hematology.

[4]  S. Miyano,et al.  Dynamics of clonal evolution in myelodysplastic syndromes , 2016, Nature Genetics.

[5]  A. Trumpp,et al.  Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. , 2016, Blood.

[6]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[7]  Michelle C. Chen,et al.  Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9 , 2016, Nature Medicine.

[8]  C. Hernández-Munain,et al.  Functional Consequences for Apoptosis by Transcription Elongation Regulator 1 (TCERG1)-Mediated Bcl-x and Fas/CD95 Alternative Splicing , 2015, PloS one.

[9]  S. Miyano,et al.  Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. , 2015, Cancer cell.

[10]  G. Mufti,et al.  CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis. , 2015, The Lancet. Haematology.

[11]  K. Döhner,et al.  Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q , 2015, Leukemia.

[12]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[13]  B. Ebert,et al.  Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. , 2014, Cancer cell.

[14]  Weixin Yao,et al.  Fully Bayesian logistic regression with hyper-LASSO priors for high-dimensional feature selection , 2014, Journal of Statistical Computation and Simulation.

[15]  M. L. Le Beau,et al.  Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. , 2014, Blood.

[16]  A. Jankowska,et al.  Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Boultwood.  The role of haploinsufficiency of RPS14 and p53 activation in the molecular pathogenesis of the 5q- syndrome , 2011, Pediatric reports.

[18]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[19]  D. Levens,et al.  Isolation and Characterization of a Novel H1.2 Complex That Acts as a Repressor of p53-mediated Transcription* , 2008, Journal of Biological Chemistry.

[20]  T. Mustelin,et al.  A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells , 2007, Cell Death and Differentiation.

[21]  D. Lane,et al.  Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo* , 2004, Journal of Biological Chemistry.

[22]  V. Najfeld,et al.  Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia , 2001, Leukemia.

[23]  G. Mufti,et al.  The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. , 2000, Blood.

[24]  A. Monaco,et al.  Novel genes mapping to the critical region of the 5q- syndrome. , 1997, Genomics.

[25]  R. Espinosa,et al.  Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Fryns,et al.  Distinct haematological disorder with deletion of long arm of No. 5 chromosome , 1974, Nature.

[27]  J. Reinstein,et al.  Bap (Sil1) regulates the molecular chaperone BiP by coupling release of nucleotide and substrate , 2017, Nature Structural & Molecular Biology.

[28]  Michael F Clarke,et al.  Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation , 2007, Nature Medicine.

[29]  C. Schoch,et al.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.